Chaturvedula, S.; Diver, D.J.; Vashist, A. Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma. Preprints2018, 2018020084. https://doi.org/10.20944/preprints201802.0084.v1
APA Style
Chaturvedula, S., Diver, D.J., & Vashist, A. (2018). Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma. Preprints. https://doi.org/10.20944/preprints201802.0084.v1
Chicago/Turabian Style
Chaturvedula, S., Daniel J. Diver and Aseem Vashist. 2018 "Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma" Preprints. https://doi.org/10.20944/preprints201802.0084.v1
Abstract
Percutaneous coronary intervention(PCI) with stenting for the treatment of acute coronary syndrome(ACS) is the contemporary standard of care. Such treatment is followed by Dual anti-platelet therapy(DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. Decision regarding DAPT duration can be challenging clinically in the modern era with the evolution of newer stents, more potent antiplatelet agents and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging "shared decision making". The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy.
Keywords
dual anti platelet therapy; acute coronary syndrome; stents
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
